Navigation Links
AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing

RANCHO CORDOVA, Calif., Jan. 25, 2012 /PRNewswire/ -- AMPAC Fine Chemicals LLC (AFC), a wholly owned subsidiary of American Pacific Corporation (Nasdaq: APFC), announced today that is has been granted Registration as a Manufacturer of Controlled Substances from the U.S. Drug Enforcement Agency (DEA).

AFC has been involved in the development of Schedule II Controlled Substances since 2008 under a Researcher's License from the DEA.  Recent facilities upgrades have expanded AFC's capabilities to include commercial scale manufacturing of Schedule II controlled substances.  This manufacturing is conducted within a high security area of AFC's Rancho Cordova, California, facilities, which are located within a Department of Defense-regulated campus. 

"AFC's upgraded controlled substance facility offers a state-of-the-art, remotely operated process plant which can safely run hydrogenations and hazardous chemical processes, while containing reactants and products with Operator Exposure Limit as low as 0.5 micrograms per cubic meter. The recent upgrades satisfy DEA requirements for producing Schedule II intermediates and active pharmaceutical ingredients under current Good Manufacturing Practices (cGMP)," stated Larry Zeagler, Executive Director of Product Management for AFC.

"We are pleased to add controlled substance commercial manufacturing to the value proposition that we bring to our customers.  This major milestone enhances our position as a fine chemical supplier with world-class cGMP manufacturing capabilities in the United States," stated Aslam Malik, President of AFC.

AFC's entry into the field of controlled substances is enabled by a commercial arrangement with a large pharmaceutical company. These developments position AFC for significant growth in the controlled substances area.

AFC is a U.S.-based company with demonstrated capabilities in process development, scale-up, and cGMP-compliant commercial production of active pharmaceutical ingredients (API's) and registered intermediates for pharmaceutical and biotechnology customers. Its specially engineered facilities and experienced staff allow AFC to safely produce highly energetic compounds at commercial scale. In addition, AFC's other technology platforms include production of highly potent compounds, continuous processes and industrial-scale chromatographic separation using simulated moving bed chromatography (SMB).  AFC's operations are located in Rancho Cordova, CA, and in La Porte, Texas.  Additional information about us can be obtained by visiting our web site at

American Pacific Corporation (AMPAC) is a leading custom manufacturer of fine chemicals, specialty chemicals and propulsion products within its focused markets. We supply active pharmaceutical ingredients and advanced intermediates to the pharmaceutical industry. For the aerospace and defense industry we provide specialty chemicals used in solid rocket motors for space launch and military missiles. AMPAC also designs and manufactures liquid propulsion systems, valves and structures for space and missile defense applications. We produce clean agent chemicals for the fire protection industry, as well as electro-chemical equipment for the water treatment industry. Our products are designed to meet customer specifications and often must meet certain governmental and regulatory approvals. Additional information about us can be obtained by visiting our web site at

Statements contained in this press release that are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including without limitation statements regarding anticipated benefits and outcomes of the Registration of AFC as a Manufacturer of Controlled Substances by the DEA. The inclusion of forward-looking statements should not be regarded as a representation by American Pacific Corporation and its affiliates (collectively, "American Pacific") that any of American Pacific's expectations will be achieved.  Actual results may differ materially from future results or outcomes expressed or implied by forward-looking statements set forth in this press release due to risks, uncertainties and other important factors inherent in American Pacific's business.  Factors that might cause actual results to differ include, but are not limited to, those included in the "Risk Factors" section of the Form 10-K for the fiscal year ended September 30, 2011, filed by American Pacific Corporation with the U.S. Securities and Exchange Commission.  Readers of this press release are referred to the filings of American Pacific Corporation with the U.S. Securities and Exchange Commission  or further discussion of these and other factors that could affect future results. The forward-looking statements contained in this press release are made as of the date hereof and American Pacific assumes no obligation to update for actual results or to update the reasons why actual results could differ materially from those projected in the forward-looking statements, except as required by law.  Technical Contact:


William DuBay, Ph.D., Vice President,

Technology and Business Development 


AMPAC Fine Chemicals 


+1 (800) 311-9668

+1 (916) 357-6880 


 Investor Contact:


Deanna Riccardi 


American Pacific Corporation 


+1 (702) 735-2200

SOURCE American Pacific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AMPAC Fine Chemicals Names Terry Vollrath Vice President of Operations
2. AMPAC Fine Chemicals Adds New Capabilities for Clinical Programs
3. Ampac Fine Chemicals President Aslam Malik Joins SOCMAs Board of Governors; Industry Veteran Adds Significant Experience to Board
4. AMPAC Fine Chemicals Partners With Inabata & Co., Ltd. of Japan
5. AMPAC Fine Chemicals Receives Prestigious Award at Californias Annual Statewide Environmental Summit
6. The Global Pharmaceutical Fine Chemicals Market Outlook to 2015
7. European Fine Chemicals Group Ratifies FDAs Proposed Generic Drug User Fees Act (GDUFA)
8. Reportlinker Adds The Global Pharmaceutical Fine Chemicals Market Outlook to 2015
9. New ionator EXP(TM) and ionator HOM(TM) Kill Swine Flu Without Use of Chemicals
10. Sigma-Aldrich Becomes the Sole U.S. and Canada Distributor of Kromasil(R) HPLC Columns Through Agreement With Eka Chemicals
11. Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey
Post Your Comments:
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud ... and unique items from across the nation, this holiday-themed event will raise funds and ... the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and fastest ... to open a flagship location in Covington, LA at 401 N. U.S. Highway 190, ... next to Office Depot in the Holiday Square shopping center. Its location allows it ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
Breaking Medicine News(10 mins):